The UK's Mereo BioPharma Group PLC is to get the US listing it had been seeking by merging with troubled California-based Oncomed Pharmaceuticals Inc., adding cash and a couple of investigational cancer drugs.
In an interview with Scrip just after the deal was announced (Dec. 5), Mereo CEO Denise Scots-Knight noted that after postponing plans for a US offering in April, which would...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?